{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:52:49Z","timestamp":1792601569095,"version":"4.5.0"},"reference-count":165,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED), a vision-threatening and disfiguring autoimmune process, has thwarted our efforts to understand its pathogenesis and develop effective and safe treatments. Recent scientific advances have facilitated improved treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Review historically remote and recent advances in understanding TED.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design\/Setting\/Participants<\/jats:title>\n                    <jats:p>PubMed was scanned using search terms including thyroid-associated ophthalmopathy, thyroid eye disease, Graves\u2019 orbitopathy, autoimmune thyroid disease, and orbital inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Strength of scientific evidence, size, scope, and controls of clinical trials\/observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Glucocorticoid steroids are widely prescribed systemic medical therapy. They can lessen inflammation-related manifestations of TED but fail to reliably reduce proptosis and diplopia, 2 major causes of morbidity. Other current therapies include mycophenolate, rituximab (anti-CD20 B cell-depleting monoclonal antibody), tocilizumab (interleukin-6 receptor antagonist), and teprotumumab (IGF-I receptor inhibitor). Several new therapeutic approaches have been proposed including targeting prostaglandin receptors, vascular endothelial growth factor, mTOR, and cholesterol pathways. Of potentially greater long-term importance are attempts to restore immune tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite their current wide use, steroids may no longer enjoy first-tier status for TED as more effective and better tolerated medical options become available. Multiple current and emerging therapies, the rationales for which are rooted in theoretical and experimental science, promise better options. These include teprotumumab, rituximab, and tocilizumab. Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac328","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:23:30Z","timestamp":1659961410000},"page":"S13-S26","source":"Crossref","is-referenced-by-count":51,"title":["Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6279-9685","authenticated-orcid":false,"given":"Terry J","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan Medical School , Ann Arbor, MI 48105 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"2022121404063098000_CIT0001","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med."},{"key":"2022121404063098000_CIT0002","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0003","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci."},{"key":"2022121404063098000_CIT0004","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0005","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/thy.2008.0033","article-title":"Advances in surgical rehabilitation in thyroid eye disease","volume":"18","author":"Goldberg","year":"2008","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0006","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1210\/endo-95-2-434","article-title":"Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane","volume":"95","author":"Konishi","year":"1974","journal-title":"Endocrinology."},{"key":"2022121404063098000_CIT0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0303-7207(78)90072-2","article-title":"Thyrotropin receptors in adipose tissue, retro-orbital tissue and lymphocytes","volume":"9","author":"Davies","year":"1978","journal-title":"Mol Cell Endocrinol."},{"key":"2022121404063098000_CIT0008","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/eye.2013.120","article-title":"Relevance of TSH-receptor antibody levels in predicting disease course in Graves\u2019 orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay","volume":"27","author":"Jang","year":"2013","journal-title":"Eye (Lond)."},{"key":"2022121404063098000_CIT0009","first-page":"160008","article-title":"Thyroid antibody-negative euthyroid Graves\u2019 ophthalmopathy","volume":"2016","author":"Tabasum","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"2022121404063098000_CIT0010","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","article-title":"Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation","volume":"154","author":"Moshkelgosha","year":"2013","journal-title":"Endocrinology."},{"key":"2022121404063098000_CIT0011","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0012","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0013","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0014","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0015","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.4049\/jimmunol.173.5.3564","article-title":"Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves\u2019 disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor","volume":"173","author":"Pritchard","year":"2004","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0016","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0017","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2012-2270","article-title":"Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves\u2019 ophthalmopathy","volume":"98","author":"Varewijck","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0018","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy","volume":"98","author":"Minich","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence that Graves\u2019 ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","article-title":"Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts","volume":"168","author":"Pritchard","year":"2002","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0021","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133258","article-title":"Activation of the IGF axis in thyroid cancer: implications for tumorigenesis and treatment","volume":"20","author":"Manzella","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2022121404063098000_CIT0022","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0023","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac045","article-title":"IGF-I receptor, TSH receptor and thyroid eye disease","author":"Girnita","year":"2022","journal-title":"J Endocrinol Metab."},{"key":"2022121404063098000_CIT0024","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1001\/archopht.1985.01050050048015","article-title":"Lymphocyte subpopulations in Graves\u2019 ophthalmopathy","volume":"103","author":"Felberg","year":"1985","journal-title":"Arch Ophthalmol."},{"key":"2022121404063098000_CIT0025","first-page":"1120","article-title":"Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves\u2019 ophthalmopathy","volume":"77","author":"de Carli","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0026","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1172\/JCI117289","article-title":"Retrobulbar T cells from patients with Graves\u2019 ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts","volume":"93","author":"Grubeck-Loebenstein","year":"1994","journal-title":"J Clin Invest."},{"key":"2022121404063098000_CIT0027","doi-asserted-by":"crossref","first-page":"E400","DOI":"10.1210\/jc.2011-2697","article-title":"Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves\u2019 ophthalmopathy","volume":"97","author":"van Steensel","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0028","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1210\/endo.140.8.6881","article-title":"HMC-1 mast cells activate human orbital fibroblasts in coculture: evidence for up-regulation of prostaglandin E2 and hyaluronan synthesis","volume":"140","author":"Smith","year":"1999","journal-title":"Endocrinology."},{"key":"2022121404063098000_CIT0029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol Med."},{"key":"2022121404063098000_CIT0030","first-page":"2620","article-title":"Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts","volume":"80","author":"Smith","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0031","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","article-title":"Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0032","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","article-title":"Increased generation of fibrocytes in thyroid-associated ophthalmopathy","volume":"95","author":"Douglas","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0033","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0002-9440(10)63488-8","article-title":"Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes","volume":"163","author":"Koumas","year":"2003","journal-title":"Am J Pathol."},{"key":"2022121404063098000_CIT0034","doi-asserted-by":"crossref","first-page":"22910","DOI":"10.1074\/jbc.M703597200","article-title":"Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma","volume":"282","author":"Hong","year":"2007","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0035","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.94.12.6307","article-title":"The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ","volume":"94","author":"Chesney","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022121404063098000_CIT0036","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114244118","article-title":"Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy","author":"Fernando","year":"2021","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022121404063098000_CIT0037","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1073\/pnas.1202064109","article-title":"Human fibrocytes coexpress thyroglobulin and thyrotropin receptor","volume":"109","author":"Fernando","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022121404063098000_CIT0038","doi-asserted-by":"crossref","first-page":"E1236","DOI":"10.1210\/jc.2013-4271","article-title":"Expression of thyrotropin receptor, thyroglobulin, sodium-iodide symporter, and thyroperoxidase by fibrocytes depends on AIRE","volume":"99","author":"Fernando","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0039","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.4049\/jimmunol.1800259","article-title":"Slit2 modulates the inflammatory phenotype of orbit-infiltrating fibrocytes in Graves\u2019 disease","volume":"200","author":"Fernando","year":"2018","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0040","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1210\/clinem\/dgaa684","article-title":"Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy","volume":"106","author":"Fernando","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0041","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.4049\/jimmunol.1900434","article-title":"Slit2 may underlie divergent induction by thyrotropin of IL-23 and IL-12 in human fibrocytes","volume":"204","author":"Fernando","year":"2020","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0042","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/jc.2018-01626","article-title":"Insights into local orbital immunity: evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy","volume":"104","author":"Fang","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0043","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1167\/iovs.16-20199","article-title":"IL-17A promotes RANTES expression, but not IL-16, in orbital fibroblasts via CD40-CD40L combination in thyroid-associated ophthalmopathy","volume":"57","author":"Fang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2022121404063098000_CIT0044","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1210\/jc.2016-1882","article-title":"IL-17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO","volume":"101","author":"Fang","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0045","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1167\/iovs.14-14002","article-title":"Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy","volume":"55","author":"Wang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2022121404063098000_CIT0046","first-page":"222","article-title":"Immunohistochemical analysis of the retrobulbar tissues in Graves\u2019 ophthalmopathy","volume":"75","author":"Weetman","year":"1989","journal-title":"Clin Exp Immunol."},{"key":"2022121404063098000_CIT0047","first-page":"348","article-title":"Molecular cloning and characterization of genes for antibodies generated by orbital tissue-infiltrating B-cells in Graves\u2019 ophthalmopathy","volume":"78","author":"Jaume","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0048","first-page":"213","article-title":"Unique properties of orbital connective tissue underlie its involvement in Graves\u2019 disease","volume":"28","author":"Smith","year":"2003","journal-title":"Minerva Endocrinol."},{"key":"2022121404063098000_CIT0049","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0050","doi-asserted-by":"crossref","first-page":"22718","DOI":"10.1074\/jbc.271.37.22718","article-title":"Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation","volume":"271","author":"Wang","year":"1996","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0051","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.273.45.29615","article-title":"Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy","volume":"273","author":"Cao","year":"1998","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0052","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.4049\/jimmunol.179.10.7147","article-title":"Jak2 dampens the induction by IL-1beta of prostaglandin endoperoxide H synthase 2 expression in human orbital fibroblasts: evidence for divergent influence on the prostaglandin E2 biosynthetic pathway","volume":"179","author":"Han","year":"2007","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0053","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1167\/iovs.08-2328","article-title":"Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1","volume":"50","author":"Hwang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2022121404063098000_CIT0054","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1210\/jcem-72-5-1169","article-title":"Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts","volume":"72","author":"Smith","year":"1991","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0055","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.164.7.3806","article-title":"Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism","volume":"164","author":"Sciaky","year":"2000","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0056","doi-asserted-by":"crossref","first-page":"24487","DOI":"10.1074\/jbc.M111.241166","article-title":"Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease","volume":"286","author":"Tsui","year":"2011","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0057","article-title":"2021 update on thyroid-associated ophthalmopathy","author":"Neag","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0058","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/146642409111100506","article-title":"Oxygen free radicals and human diseases","volume":"111","author":"Aruoma","year":"1991","journal-title":"J R Soc Health."},{"key":"2022121404063098000_CIT0059","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.imlet.2004.03.020","article-title":"Peripheral parameters of oxidative stress in patients with infiltrative Graves\u2019 ophthalmopathy treated with corticosteroids","volume":"93","author":"Bednarek","year":"2004","journal-title":"Immunol Lett."},{"key":"2022121404063098000_CIT0060","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/thy.2020.0238","article-title":"Downregulation of caveolin-1 and upregulation of deiodinase 3, associated with hypoxia-inducible factor-1\u03b1 increase, are involved in the oxidative stress of Graves\u2019 orbital adipocytes","volume":"31","author":"Van Regemorter","year":"2021","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0061","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2016-1279","article-title":"Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in Graves\u2019 ophthalmopathy-implications for smoking","volume":"101","author":"G\u00f6rtz","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0062","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/01676830.2018.1553191","article-title":"Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves\u2019 ophthalmopathy","volume":"38","author":"Yuksel","year":"2019","journal-title":"Orbit."},{"key":"2022121404063098000_CIT0063","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40618-017-0718-7","article-title":"Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves\u2019 orbitopathy (GO): a new frontier for GO treatment?","volume":"41","author":"Rotondo Dottore","year":"2018","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0064","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med."},{"key":"2022121404063098000_CIT0065","doi-asserted-by":"crossref","first-page":"799602","DOI":"10.3389\/fmicb.2022.799602","article-title":"Characteristics of the gut microbiome and its relationship with peripheral CD4(+) T cell subpopulations and cytokines in rheumatoid arthritis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol."},{"key":"2022121404063098000_CIT0066","doi-asserted-by":"crossref","first-page":"746998","DOI":"10.3389\/fimmu.2021.746998","article-title":"Causal relationship between gut microbiota and autoimmune diseases: a two-sample mendelian randomization study","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol."},{"key":"2022121404063098000_CIT0067","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/genes12081181","article-title":"Host genetics and gut microbiome: perspectives for multiple sclerosis","volume":"12","author":"Maglione","year":"2021","journal-title":"Genes."},{"key":"2022121404063098000_CIT0068","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","article-title":"Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases","volume":"18","author":"Yang","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"2022121404063098000_CIT0069","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/annrheumdis-2021-221267","article-title":"Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease","volume":"81","author":"Tomofuji","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"2022121404063098000_CIT0070","doi-asserted-by":"crossref","DOI":"10.3390\/nu13103376","article-title":"Targeting probiotics in rheumatoid arthritis","volume":"13","author":"Bungau","year":"2021","journal-title":"Nutrients."},{"key":"2022121404063098000_CIT0071","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40618-016-0594-6","article-title":"The thyroid, the eyes and the gut: a possible connection","volume":"40","author":"Covelli","year":"2017","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0072","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40168-018-0478-4","article-title":"Gut microbiota in experimental murine model of Graves\u2019 orbitopathy established in different environments may modulate clinical presentation of disease","volume":"6","author":"Masetti","year":"2018","journal-title":"Microbiome."},{"key":"2022121404063098000_CIT0073","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40618-019-1010-9","article-title":"Alterations in the intestinal microbiota of patients with severe and active Graves\u2019 orbitopathy: a cross-sectional study","volume":"42","author":"Shi","year":"2019","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0074","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa511","article-title":"Gut dysbiosis contributes to the imbalance of Treg and Th17 cells in Graves\u2019 disease patients by propionic acid","volume":"105","author":"Su","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00952-4","article-title":"Modulating gut microbiota in a mouse model of Graves\u2019 orbitopathy and its impact on induced disease","volume":"9","author":"Moshkelgosha","year":"2021","journal-title":"Microbiome."},{"key":"2022121404063098000_CIT0076","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00417-014-2662-y","article-title":"Increased serum VEGF and b-FGF in Graves\u2019 ophthalmopathy","volume":"252","author":"Ye","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"2022121404063098000_CIT0077","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.ophtha.2016.05.052","article-title":"Orbital angiogenesis and lymphangiogenesis in thyroid eye disease: an analysis of vascular growth factors with clinical correlation","volume":"123","author":"Wong","year":"2016","journal-title":"Ophthalmology."},{"key":"2022121404063098000_CIT0078","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40618-019-01174-8","article-title":"Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids","volume":"43","author":"Xu","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0079","first-page":"657","article-title":"Prednisone therapy in ophthalmic Graves\u2019 disease","volume":"81","author":"Evans","year":"1961","journal-title":"Trans Ophthalmol Soc U K."},{"key":"2022121404063098000_CIT0080","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0081","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0082","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrendo.2009.61","article-title":"Graves orbitopathy: a perspective","volume":"5","author":"Perros","year":"2009","journal-title":"Nat Rev Endocrinol."},{"key":"2022121404063098000_CIT0083","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1073\/pnas.91.2.752","article-title":"Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor","volume":"91","author":"Ray","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022121404063098000_CIT0084","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1016\/S0021-9258(17)37586-5","article-title":"12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter","volume":"269","author":"van de Stolpe","year":"1994","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0085","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1074\/jbc.M111246200","article-title":"Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression","volume":"277","author":"Han","year":"2002","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0086","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF03345386","article-title":"Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves\u2019 ophthalmopathy treated successfully with glucocorticoids themselves","volume":"28","author":"Marino","year":"2005","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0087","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1530\/EJE-11-0779","article-title":"Fatal and non-fatal adverse events of glucocorticoid therapy for Graves\u2019 orbitopathy: a questionnaire survey among members of the European Thyroid Association","volume":"166","author":"Marcocci","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0088","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev."},{"key":"2022121404063098000_CIT0089","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","article-title":"Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves\u2019 ophthalmopathy","volume":"17","author":"Le Moli","year":"2007","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12020-016-0928-3","article-title":"Acute liver damage following intravenous glucocorticoid treatment for Graves\u2019 ophthalmopathy","volume":"54","author":"Moleti","year":"2016","journal-title":"Endocrine."},{"key":"2022121404063098000_CIT0091","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy","volume":"80","author":"Kauppinen-M\u00e4kelin","year":"2002","journal-title":"Acta Ophthalmol Scand."},{"key":"2022121404063098000_CIT0092","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0093","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study","volume":"158","author":"van Geest","year":"2008","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0094","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022121404063098000_CIT0096","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol."},{"key":"2022121404063098000_CIT0097","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1093\/ndt\/gfh445","article-title":"Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients","volume":"19","author":"Meier-Kriesche","year":"2004","journal-title":"Nephrol Dial Transplant."},{"key":"2022121404063098000_CIT0098","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0041-1345(02)03538-8","article-title":"Mechanisms of action of mycophenolate mofetil in preventing chronic rejection","volume":"34","author":"Allison","year":"2002","journal-title":"Transplant Proc."},{"key":"2022121404063098000_CIT0099","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1124\/dmd.110.034249","article-title":"Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil","volume":"38","author":"Fujiyama","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"2022121404063098000_CIT0100","doi-asserted-by":"crossref","first-page":"27286","DOI":"10.1016\/S0021-9258(19)74247-1","article-title":"Characterization of human type I and type II IMP dehydrogenases","volume":"268","author":"Carr","year":"1993","journal-title":"J Biol Chem."},{"key":"2022121404063098000_CIT0101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbi.2018.09.020","article-title":"Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1\u03b2 mediated PI3K\/AKT\/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy","volume":"75","author":"Mazumder","year":"2019","journal-title":"Brain Behav Immun."},{"key":"2022121404063098000_CIT0102","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-21-0861","article-title":"Comment on the 2021 EUGOGO clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","author":"Smith","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0103","article-title":"Reply to: comment on EUGOGO clinical practice guidelines","author":"Kahaly","year":"2021","journal-title":"Eur J Endocrinol."},{"key":"2022121404063098000_CIT0104","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J Endocrinol Invest."},{"key":"2022121404063098000_CIT0105","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1186\/ar4261","article-title":"Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration","volume":"15","author":"Prieto-Pot\u00edn","year":"2013","journal-title":"Arthritis Res Ther."},{"key":"2022121404063098000_CIT0106","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1756-185X.12999","article-title":"New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis","volume":"20","author":"Mahmoudi","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"2022121404063098000_CIT0107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022121404063098000_CIT0108","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jdi.13271","article-title":"Statin-induced autoimmune hepatitis in patients with type 1 diabetes: A report of two cases and literature review","volume":"11","author":"Kawasaki","year":"2020","journal-title":"J Diabetes Investig."},{"key":"2022121404063098000_CIT0109","doi-asserted-by":"crossref","first-page":"21501327211028714","DOI":"10.1177\/21501327211028714","article-title":"Statin-induced autoimmune necrotizing myopathy","volume":"12","author":"Jayatilaka","year":"2021","journal-title":"J Prim Care Community Health."},{"key":"2022121404063098000_CIT0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12974-022-02409-x","article-title":"Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis","volume":"19","author":"Vigne","year":"2022","journal-title":"J Neuroinflammation."},{"key":"2022121404063098000_CIT0111","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2014.03.004","article-title":"Role of statins in the treatment of multiple sclerosis","volume":"87","author":"Ciurleo","year":"2014","journal-title":"Pharmacol Res."},{"key":"2022121404063098000_CIT0112","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1210\/clinem\/dgaa161","article-title":"Novel roles of chloroquine and hydroxychloroquine in Graves\u2019 orbitopathy therapy by targeting orbital fibroblasts","volume":"105","author":"Guo","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0113","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/cen.13834","article-title":"Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach","volume":"89","author":"Sipkova","year":"2018","journal-title":"Clin Endocrinol."},{"key":"2022121404063098000_CIT0114","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/thy.2006.16.709","article-title":"Treatment-resistant severe, active Graves\u2019 ophthalmopathy successfully treated with B lymphocyte depletion","volume":"16","author":"El Fassi","year":"2006","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","journal-title":"Ophthalmology."},{"key":"2022121404063098000_CIT0116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0117","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0118","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity."},{"key":"2022121404063098000_CIT0119","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med."},{"key":"2022121404063098000_CIT0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med."},{"key":"2022121404063098000_CIT0121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-020-01287-y","article-title":"Teprotumumab: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs."},{"key":"2022121404063098000_CIT0122","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-013-2372-x","article-title":"Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies","volume":"73","author":"Mahadevan","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"key":"2022121404063098000_CIT0123","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022121404063098000_CIT0124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fnmol.2011.00011","article-title":"The role of insulin-like growth factor-I in the physiopathology of hearing","volume":"4","author":"Murillo-Cuesta","year":"2011","journal-title":"Front Mol Neurosci."},{"key":"2022121404063098000_CIT0125","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1523\/JNEUROSCI.21-19-07630.2001","article-title":"Delayed inner ear maturation and neuronal loss in postnatal Igf-1-deficient mice","volume":"21","author":"Camarero","year":"2001","journal-title":"J Neurosci."},{"key":"2022121404063098000_CIT0126","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mcn.2013.03.003","article-title":"Insulin-like growth factor 1 inhibits hair cell apoptosis and promotes the cell cycle of supporting cells by activating different downstream cascades after pharmacological hair cell injury in neonatal mice","volume":"56","author":"Hayashi","year":"2013","journal-title":"Mol Cell Neurosci."},{"key":"2022121404063098000_CIT0127","article-title":"Rifle blast exacerbating hearing loss in a patient treated with teprotumumab for thyroid eye disease","author":"Reed","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg."},{"key":"2022121404063098000_CIT0128","doi-asserted-by":"crossref","first-page":"101202","DOI":"10.1016\/j.ajoc.2021.101202","article-title":"Audiology findings in patients with teprotumumab associated otologic symptoms","volume":"24","author":"Yu","year":"2021","journal-title":"Am J Ophthalmol Case Rep."},{"key":"2022121404063098000_CIT0129","first-page":"1945998211004240","article-title":"Thyroid eye disease, teprotumumab, and hearing loss: an evolving role for otolaryngologists","author":"Chern","year":"2021","journal-title":"Otolaryngol Head Neck Surg."},{"key":"2022121404063098000_CIT0130","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ Case Rep."},{"key":"2022121404063098000_CIT0131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4615-3448-8_4","article-title":"The effects of IGF-I and IGF-II on cell growth and differentiation in the central nervous system","volume":"321","author":"Lauterio","year":"1992","journal-title":"Adv Exp Med Biol."},{"key":"2022121404063098000_CIT0132","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02740625","article-title":"The role of the insulin-like growth factors in the central nervous system","volume":"13","author":"D\u2019Ercole","year":"1996","journal-title":"Mol Neurobiol."},{"key":"2022121404063098000_CIT0133","article-title":"Mechanisms in Graves eye disease: apoptosis as the end point of igf-1 receptor inhibition","author":"Morshed","year":"2021","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0134","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int Immunopharmacol."},{"key":"2022121404063098000_CIT0135","first-page":"4371","article-title":"Leukemia inhibitory factor and interleukin-6 trigger the same immediate early response, including tyrosine phosphorylation, upon induction of myeloid leukemia differentiation","volume":"11","author":"Lord","year":"1991","journal-title":"Mol Cell Biol."},{"key":"2022121404063098000_CIT0136","first-page":"1657","article-title":"The signalling pathways of interleukin-6 and g interferon converge by the activation of different transcription factors which bind to common responsive DNA elements","volume":"14","author":"Yuan","year":"1994","journal-title":"Mol Cell Biol."},{"key":"2022121404063098000_CIT0137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0896-8411(89)90128-5","article-title":"Intrathyroidal cytokine production in thyroid disease","volume":"2","author":"Grubeck-Loebenstein","year":"1989","journal-title":"J Autoimmun."},{"key":"2022121404063098000_CIT0138","first-page":"1194","article-title":"Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy","volume":"85","author":"Hiromatsu","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0139","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","article-title":"Humanized antihuman IL-6 receptor antibody, tocilizumab","author":"Nishimoto","year":"2008","journal-title":"Handb Exp Pharmacol."},{"key":"2022121404063098000_CIT0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med."},{"key":"2022121404063098000_CIT0141","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"Perez-Moreiras","year":"2014","journal-title":"Ophthal Plast Reconstr Surg."},{"key":"2022121404063098000_CIT0142","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol."},{"key":"2022121404063098000_CIT0143","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med."},{"key":"2022121404063098000_CIT0144","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2020","journal-title":"Ocul Immunol Inflamm."},{"key":"2022121404063098000_CIT0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet (London, England)."},{"key":"2022121404063098000_CIT0146","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1210\/en.2008-0836","article-title":"A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism","volume":"149","author":"Neumann","year":"2008","journal-title":"Endocrinology."},{"key":"2022121404063098000_CIT0147","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol."},{"key":"2022121404063098000_CIT0148","first-page":"19","article-title":"Autoimmune highlight","volume":"3","author":"Furmaniak","year":"2011"},{"key":"2022121404063098000_CIT0149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13317-019-0121-9","article-title":"Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70(TM) a human monoclonal autoantibody to the TSH receptor with TSH antagonist activity","volume":"10","author":"Furmaniak","year":"2019","journal-title":"Auto Immun Highlights."},{"key":"2022121404063098000_CIT0150","doi-asserted-by":"crossref","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-results from a phase I clinical trial","author":"Furmaniak","year":"2022","journal-title":"Clin Endocrinol."},{"key":"2022121404063098000_CIT0151","first-page":"1597","article-title":"Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves\u2019 disease, and Graves\u2019 ophthalmopathy","volume":"31","author":"Ryder","year":"2021","journal-title":"Thyroid."},{"key":"2022121404063098000_CIT0152","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/clin.1997.4391","article-title":"Coexpression of CD40 and class II antigen HLA-DR in Graves\u2019 disease thyroid epithelial cells","volume":"84","author":"Faure","year":"1997","journal-title":"Clin Immunol Immunopathol."},{"key":"2022121404063098000_CIT0153","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz013","article-title":"A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-a proof-of-concept trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0154","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.4049\/jimmunol.172.4.2021","article-title":"Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn","volume":"172","author":"Ober","year":"2004","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0155","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol."},{"key":"2022121404063098000_CIT0156","doi-asserted-by":"crossref","first-page":"118074","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRn blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J Neurol Sci."},{"key":"2022121404063098000_CIT0157","first-page":"3553","article-title":"Prostaglandin E2 alters human orbital fibroblast shape through a mechanism involving the generation of cyclic adenosine monophosphate","volume":"80","author":"Wang","year":"1995","journal-title":"J Clin Endocrinol Metab."},{"key":"2022121404063098000_CIT0158","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1167\/iovs.18-25134","article-title":"The effect of prostaglandin analogue bimatoprost on thyroid-associated orbitopathy","volume":"59","author":"Choi","year":"2018","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"2022121404063098000_CIT0159","doi-asserted-by":"crossref","first-page":"108489","DOI":"10.1016\/j.exer.2021.108489","article-title":"Prostaglandin F2\u03b1 and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave\u2019s orbitopathy related human orbital fibroblasts","volume":"205","author":"Ichioka","year":"2021","journal-title":"Exp Eye Res."},{"key":"2022121404063098000_CIT0160","doi-asserted-by":"crossref","first-page":"191ra","DOI":"10.1126\/scitranslmed.3006103","article-title":"Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes","volume":"5","author":"Roep","year":"2013","journal-title":"Sci Transl Med."},{"key":"2022121404063098000_CIT0161","doi-asserted-by":"crossref","first-page":"654701","DOI":"10.3389\/fimmu.2021.654701","article-title":"Potential for antigen-specific tolerizing immunotherapy in systematic lupus erythematosus","volume":"12","author":"Robinson","year":"2021","journal-title":"Front Immunol."},{"key":"2022121404063098000_CIT0162","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"2022121404063098000_CIT0163","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science."},{"key":"2022121404063098000_CIT0164","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology."},{"key":"2022121404063098000_CIT0165","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/Supplement_1\/S13\/47843340\/dgac328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/Supplement_1\/S13\/47843340\/dgac328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T23:07:31Z","timestamp":1670972851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/Supplement_1\/S13\/6658347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":165,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,8,8]]},"published-print":{"date-parts":[[2022,8,8]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac328","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,8,8]]}}}